Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis - An economic evaluation

Thrombosis and Haemostasis

Volumn 79, Issue 2, 1998, Pages 259-263

  Von Den Belt, Angelique G M ^a   Bossuyt, Patrick M M ^a   Prins, Martin H ^a   Gallus, Alexander S ^b   Büller, Harry R ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; NADROPARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COST CONTROL; DEEP VEIN THROMBOSIS; FEMALE; HEALTH CARE COST; HOME CARE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031935461     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614975     Document Type: Article

References (13)

1. Prandoni P, Lensing AWA, Büller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Gate JW. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-5.
2. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Eng J Med 1992; 326; 975-82.
3. Lopaciuk S, Meissner AJ, Filipecki S, Zawilska K, Sowier J, Ciesielski L, Bielawiec M, Glowinski S, Czestochowska E. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992; 68: 14-8.
4. Lindmarker P, Holmström M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72: 186-90.
5. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep vein thrombosis with low molecular weight heparins. A Meta-analysis. Arch Intern Med 1995; 155: 601-7.
6. Koopman MMW, Prandoni P, Piovella F, Oekelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Eng J Med 1996; 334: 682-7.
7. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Eng J Med 1996; 334: 677-81.
8. Scott A. A cost analysis of early discharge and domiciliary visits versus standard hospital care for low-risk obstetric clients. Aust J Public Health 1994; 18: 96-100.
9. Drummond MF, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care 1991; 7: 561-73.
10. Koopmanschap MA, van Ineveld BM, Miltenburg ThEM. Costs of home care for advanced breast and cervical cancer in relation to cost-effectiveness of screening. Soc Sci Med 1992; 35: 979-85.
11. van Ineveld BM, van Oortmarssen GJ, de Koning HJ, Boer R, van der Maas PJ. How cost-effective is breast cancer screening in different EC countries? Eur J Cancer 1993; 29A (12): 1663-8.
12. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Dec Making 1985; 9: 1229-42.
13. Morgan M, Beech R. Variations in lengths of stay and rates of day case surgery: implications for the efficiency of surgical management. J Epidemiol Community Health 1990; 44: 90-105.